REGGIE NICHOLS: Open Payments
NPI 1699325704 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,918 in 87 payments from 14 companies in 2025. Trend: 2023 $1,574 · 2024 $2,021 · 2025 $1,918
Food & beverage: $1,918
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $403 |
| Alkermes, Inc. | 10 | $304 |
| ABBVIE INC. | 15 | $284 |
| Lundbeck LLC | 7 | $175 |
| Neurocrine BioSciences, Inc. | 5 | $172 |
| Janssen Pharmaceuticals, Inc | 7 | $151 |
| Teva Pharmaceuticals USA, Inc. | 4 | $86 |
| E.R. Squibb & Sons, L.L.C. | 4 | $77 |
| Vanda Pharmaceuticals Inc. | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
Products named: CAPLYTA, VRAYLAR, REXULTI, ARISTADA, INGREZZA, LYBALVI, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across AZ — which companies pay providers there.
